Entities / Company
Leerink partners.
U.S. investment bank
- Reports this week
- 5
- Active events
- 9
- Connections
- 221
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
-
Leerink Partners provided coverage and price targets for Freenome on September 26, 2026.Some support2 reports
-
Leerink Partners started coverage on ANI Pharmaceuticals shares.Some support3 reports
-
Leerink partners and Jefferies Financial Group issued ratings for Latigo Biotherapeutics, which also appointed Todd Smith as CEO.Some support2 reports
-
MarketBeat provided stock average ratings while Leerink Partners upgraded and Barclays raised its price objective for Summit Therapeutics.Some support1 report
-
Jefferies, Citigroup, and Leerink Partners issued rating updates and price targets for Phathom Pharmaceuticals.Some support1 report
-
Leerink Partners cut its shares rating for Akebia Therapeutics on November 3, 2026.Some support1 report
-
Illumina and Leerink partners are involved in a new development.Some support1 report
-
Leerink Partners reduced its target price for Keros Therapeutics on November 2, 2026.Some support1 report
-
Leerink Partners decreased its target price on CVS Health, while BNP Paribas and Wyoming increased their holdings.Some support1 report
Earlier this month
-
Summit seeks FDA approval for its drug, which was presented at the ASCO meeting. The company is developing ivonescimab with Akeso.Well supported8 reports
-
Intuitive Surgical received a Buy rating from Leerink partners, citing increased da Vinci placements and potential benefits from Trump-era tariffs.Some support9 reports
-
Leerink Partners and Barclays raised price targets on Elevance Health, while MarketBeat reported consensus ratings.Some support1 report
-
Leerink Partners began coverage on Novogen Limited shares on October 20, 2026.Some support1 report
-
Kazia Therapeutics Limited is seeking joint bookrunning management and co-management for a proposed offering, with Leerink partners and Needham & Company involved.Well supported17 reports1 development inside
-
Leerink Partners is acting as a placement agent for First Tracks Biotherapeutics.Some support1 report
-
Citigroup raised its rating on Innate Pharma stock, which trades on the Nasdaq exchange. Leerink Partners also upgraded the rating. MarketBeat aggregates the rating data.Some support1 report1 development inside
-
Leerink Partners assumed coverage on Equillium shares, with data reported by MarketBeat from Nasdaq listed stocks.Some support1 report
-
Leerink Partners upgraded Gossamer Bio stock rating on September 26, 2026.Some support2 reports
-
Leerink Partners assumed coverage on Nektar Therapeutics shares on October 13, 2026.Some support2 reports
-
Royal Bank of Canada downgraded Caribou Biosciences stock, and Leerink partners updated its ratings on October 9, 2026.Some support2 reports
-
Leerink Partners, Truist Financial, HSBC, and Cantor Fitzgerald raised target prices on various stocks on October 9, 2026.Some support2 reports
-
Moderna's stock performance is tracked on Nasdaq while Leerink Partners leads a Nasdaq IPO, amid oil price volatility and AI regulation tests.Some support1 report
-
Citigroup reissued a market outperform rating and Leerink Partners began coverage on Rapport Therapeutics.Some support1 report
-
Leerink Partners is a joint bookrunning manager for an offering by Retension Pharmaceuticals, Inc., with the prospectus available from Boston, MA.Some support2 reports
One to three months ago
-
Leerink Partners, Cantor Fitzgerald, and Barclays acted as placement agents for Atrium on October 8, 2026.Some support1 report
-
Leerink Partners increased its price target and Morgan Stanley reiterated an overweight rating for REGENXBIO Inc.Some support1 report
-
Leerink Partners started coverage on Nautilus Biotechnology on October 6, 2026.Some support1 report
-
Leerink Partners is acting as a joint book-running manager for an offering by Spyre Therapeutics, Inc.Some support1 report
-
Analyst firm set price targets for Leerink partners' client, Twist Bioscience, on June 26, 2026. Concurrently, the CEO sold shares due to tax withholding obligations.Some support6 reports
-
A filing required by the SEC concerning McKesson Corporation shares, accompanied by analyst commentary.Well supported7 reports
-
Needham & Company issued a buy rating, and Leerink Partners began coverage of Collegium Pharmaceutical, Inc. on September 23, 2026.Some support2 reports
-
Leerink partners issued an 'outperform' rating on Teva stock, while an insider sold shares of the company.Some support3 reports
-
Analyst firm Leerink partners raised the price target for Roivant based on share count forecast on August 13, 2025.Well supported4 reports1 development inside
-
An analyst firm has provided price target recommendations for Universal Health Services.Some support1 report
-
Analyst firm upgraded price objective on 10X Genomics stock.Some support1 report
-
Leerink raised its price target for UnitedHealth Group stock.Some support2 reports
-
Leerink partners, TD Cowen, and William Blair initiated coverage and set ratings for Kailera Therapeutics.Some support1 report
-
Truist Financial and Leerink Partners raised price objectives for Eli Lilly and Company stock.Some support1 report
-
TD Cowen raised price targets for GoodRx stock.Some support1 report
-
Financial analysts reviewed Biohaven's strategic asset sales and corporate strategy following its acquisition by Pfizer.Some support1 report
-
Scribe Therapeutics completed its IPO, led by Leerink Partners, with major backing from Eli Lilly and Andreessen Horowitz.Some support2 reports
-
Leerink partners provided research reports on AirSculpt Technologies on August 17, 2026.Some support1 report
-
Leerink Partners cut price target on Stryker Corporation, and Norges Bank bought a new position in Stryker shares.Some support1 report
-
Cantor Fitzgerald and Leerink partners issued rating changes for Replimune Group, Inc. on July 13, 2026.Some support2 reports
-
Cantor Fitzgerald and Leerink Partners initiated analyst coverage on Avidity Biosciences on August 10, 2026.Some support3 reports
-
MarketBeat is providing consensus rating for Alamar Biosciences, and Leerink Partners and Bank of America have initiated coverage on the company.Some support1 report
Gone quiet
No new reports in 90+ days-
Analyst coverage is influencing stock price targets for companies including Bank of America, Eli Lilly and Company, Leerink partners, and Cantor Fitzgerald.Well supported11 reports6 developments inside
-
Halozyme's stock performance was mentioned in proximity to Leerink Partners on August 7, 2026.Some support1 report
-
LB Pharmaceuticals Inc is seeking institutional investment for a private placement, utilizing Leerink Partners as the placement agent, with BB Biotech as a key entity.Some support1 report1 development inside
-
Leerink partners began its role as the lead book-running manager for an offering on behalf of BlossomHill Therapeutics, Inc. on August 1, 2026.Some support1 report
-
Analyst downgrades are affecting Leerink partners' stock price, which is listed on the Nasdaq stock exchange.Some support2 reports
-
Leerink partners adjusted its rating and target price for Medtronic plc on July 31, 2026.Some support1 report
-
Scribe Therapeutics is based in Alameda, California, while Leerink Partners maintains an office in Boston, MA. The article also notes Goldman Sachs has an office in New York.Some support1 report
-
Leerink Partners raised price target for Thermo Fisher Scientific Inc. (TMO) on July 23, 2026.Some support2 reports
-
SpaceX's IPO was expected to top US deals, with Jack Bannister identified as senior managing director at Leerink Partners.Some support1 report
-
Leerink partners set a $152.00 target price on Encompass Health shares.Some support1 report
-
Veradermics, Incorporated is facing market challenges in the US, with analyst reports affecting its stock price.Some support3 reports
-
Arcus Biosciences' stock rating and price were influenced by analyst reports, and the company filed with the SEC regarding institutional purchases.Well supported9 reports
-
The Tennessee Department of Treasury bought a new position in stock, while Citigroup reaffirmed its 'outperform' rating and Leerink Partners set a $43.00 price objective.Some support1 report
-
The FDA granted premarket approval for the LungFX device for use with United Therapeutics, while Leerink partners maintained an Outperform rating on the company's shares.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Leerink partners this week
News at the entities that move Leerink partners most-
company TransactionalFirst Bancorp stock is listed on Nasdaq.Moves Leerink partners
-
Nasdaq OperationalAn AI stock sell-off impacted Nasdaq on November 5, 2026, following the election results.Moves Leerink partners
-
Needham & Company OperationalNeedham & Company increased its target price on Stagwell, while MarketBeat provided consensus rating data.Moves Leerink partners
-
Medpace OperationalMedpace and Microsoft are mentioned in the context of future enterprise software stocks.Moves Leerink partners
-
Cantor Fitzgerald OperationalCantor Fitzgerald raised its price target and TD Cowen upgraded its rating for Expedia Group on November 7, 2026.Moves Leerink partners
-
Regeneron Pharmaceuticals OperationalMorgan Stanley dropped price target and Cantor Fitzgerald reduced price target on Regeneron Pharmaceuticals stock.Moves Leerink partners
Connections
The 40 strongest of 221, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
BrightSpring Health Services Operational
Leerink Partners provides financial analysis and acts as a bookrunner for BrightSpring Health Services' offerings.
-
Faisal Khurshid Structural
Faisal Khurshid is employed as an analyst at Leerink Partners.
-
Nasdaq Operational
Leerink Partners actively facilitates and provides coverage for companies listing or trading on the Nasdaq exchange.
-
company Transactional
Leerink partners and the company are jointly appointed as bookrunning managers for a financial offering.
-
Jack Bannister Structural
Jack Bannister serves as a senior managing director at Leerink Partners.
-
Aquestive (United States) Transactional
Leerink partners jointly managed a stock offering for Aquestive.
-
Bristol-Myers Squibb Operational
Leerink Partners provides market commentary and rating changes regarding companies in the pharmaceutical sector.
-
Incyte Transactional
Leerink partners increased its price objective regarding Incyte.
Show all 40 connections
-
Scribe Therapeutics Operational
Leerink Partners actively influenced Scribe Therapeutics by leading its IPO and providing market ratings.
-
Needham & Company Operational
Both Needham & Company and Leerink partners are actively involved in managing a stock offering.
-
Medpace Operational
Leerink partners provided financial analysis, including a price target, on Medpace.
-
Caribou Biosciences Mentioned together
Leerink partners updated Caribou Biosciences ratings, lowering its share performance outlook.
-
Regeneron Pharmaceuticals Operational
Leerink Partners provides financial analysis and rating updates for Regeneron Pharmaceuticals.
-
Intuitive Surgical Mentioned together
Leerink Partners provides financial analysis and ratings on Intuitive Surgical, influencing its stock valuation.
-
Merck KGaA Mentioned together
Leerink partners provides financial coverage, consistently raising price targets and ratings for Merck KGaA.
-
Roivant Sciences (United States) Mentioned together
Leerink partners provides financial analysis and price targets for Roivant Sciences.
-
CVS Health Mentioned together
Leerink Partners provides financial analysis and price targets for CVS Health.
-
Medtronic plc Mentioned together
Leerink partners provides market research and analysis on Medtronic plc's stock performance.
-
Elevance Health, Inc. Mentioned together
Leerink Partners provides financial analysis and target price objectives for Elevance Health.
-
Nanobiotix Mentioned together
Leerink partners provides analyst ratings and price targets for Nanobiotix stock.
-
Arrowhead Pharmaceuticals Mentioned together
Leerink partners issued a price target and rating for Arrowhead Pharmaceuticals.
-
GoodRx Mentioned together
Leerink Partners provides financial research and price targets for GoodRx stock.
-
UnitedHealth Group Mentioned together
Leerink partners provides financial analysis, including price targets and ratings, for UnitedHealth Group stock.
-
Halozyme Therapeutics Mentioned together
Leerink Partners functions as an analyst firm, providing market research reports and assessments on Halozyme Therapeutics.
-
Vertex Pharmaceuticals Mentioned together
Leerink Partners provides market coverage and sets price targets for Vertex Pharmaceuticals shares.
-
Acadia Healthcare Mentioned together
Leerink Partners provides financial research and price objective recommendations for Acadia Healthcare.
-
Stryker Corporation Mentioned together
Leerink partners provides financial research and analyst coverage regarding Stryker Corporation's stock.
-
Encompass Health Mentioned together
Leerink Partners provides financial analysis and sets price targets for Encompass Health.
-
Insmed Transactional
Leerink Partners acted as a joint book-running manager for Insmed during a financial offering.
-
Illumina Mentioned together
Leerink partners provides financial research reports and price targets regarding Illumina.
-
Doximity Operational
Leerink Partners actively influenced Doximity's market perception by decreasing its target price.
-
United Therapeutics Mentioned together
Leerink Partners provides investment ratings and coverage on United Therapeutics stock.
-
Teva Pharmaceutical Industries Ltd. Mentioned together
Leerink Partners provides financial coverage and ratings on Teva Pharmaceutical Industries Ltd. stock.
-
Cantor Fitzgerald Operational
The two companies actively collaborate as joint bookrunning managers in financial transactions.
-
Edwards Lifesciences Operational
Leerink Partners provides market analysis, including rating changes and price targets, for Edwards Lifesciences.
-
Guardant Health Transactional
Leerink partners issued a price objective rating on Guardant Health.
-
Kymera Therapeutics Transactional
Leerink Partners served as a joint book-running manager for Kymera Therapeutics.
-
MannKind Corporation Mentioned together
Leerink Partners provides financial ratings and price targets for MannKind Corporation.
-
Arcus Biosciences Operational
Leerink partners' analyst reports and target prices are observed to influence Arcus Biosciences' stock rating and price.
-
PROCEPT BioRobotics Mentioned together
Analysts from Leerink partners issue ratings and commentary that affect PROCEPT BioRobotics' valuation.
History
Events by the month they beganNovember 2026
7 events- Leerink partners and Jefferies Financial Group issued ratings for Latigo Biotherapeutics, which also appointed Todd Smith as CEO.
- MarketBeat provided stock average ratings while Leerink Partners upgraded and Barclays raised its price objective for Summit Therapeutics.
- Jefferies, Citigroup, and Leerink Partners issued rating updates and price targets for Phathom Pharmaceuticals.
- Leerink Partners cut its shares rating for Akebia Therapeutics on November 3, 2026.
- Illumina and Leerink partners are involved in a new development.
- Leerink Partners reduced its target price for Keros Therapeutics on November 2, 2026.
- Leerink Partners decreased its target price on CVS Health, while BNP Paribas and Wyoming increased their holdings.
October 2026
14 events- Leerink Partners and Barclays raised price targets on Elevance Health, while MarketBeat reported consensus ratings.
- Leerink Partners began coverage on Novogen Limited shares on October 20, 2026.
- Leerink Partners is acting as a placement agent for First Tracks Biotherapeutics.
- Leerink Partners assumed coverage on Equillium shares, with data reported by MarketBeat from Nasdaq listed stocks.
- Leerink Partners assumed coverage on Nektar Therapeutics shares on October 13, 2026.
- Royal Bank of Canada downgraded Caribou Biosciences stock, and Leerink partners updated its ratings on October 9, 2026.
- Leerink Partners, Truist Financial, HSBC, and Cantor Fitzgerald raised target prices on various stocks on October 9, 2026.
- Moderna's stock performance is tracked on Nasdaq while Leerink Partners leads a Nasdaq IPO, amid oil price volatility and AI regulation tests.
- Citigroup reissued a market outperform rating and Leerink Partners began coverage on Rapport Therapeutics.
- Leerink Partners is a joint bookrunning manager for an offering by Retension Pharmaceuticals, Inc., with the prospectus available from Boston, MA.
- Leerink Partners, Cantor Fitzgerald, and Barclays acted as placement agents for Atrium on October 8, 2026.
- Leerink Partners increased its price target and Morgan Stanley reiterated an overweight rating for REGENXBIO Inc.
- Leerink Partners started coverage on Nautilus Biotechnology on October 6, 2026.
- Leerink Partners is acting as a joint book-running manager for an offering by Spyre Therapeutics, Inc.
September 2026
9 events- Leerink Partners provided coverage and price targets for Freenome on September 26, 2026.
- Leerink Partners started coverage on ANI Pharmaceuticals shares.
- Leerink Partners upgraded Gossamer Bio stock rating on September 26, 2026.
- Needham & Company issued a buy rating, and Leerink Partners began coverage of Collegium Pharmaceutical, Inc. on September 23, 2026.
- Leerink partners issued an 'outperform' rating on Teva stock, while an insider sold shares of the company.
- An analyst firm has provided price target recommendations for Universal Health Services.
- Analyst firm upgraded price objective on 10X Genomics stock.
- Leerink partners, TD Cowen, and William Blair initiated coverage and set ratings for Kailera Therapeutics.
- Truist Financial and Leerink Partners raised price objectives for Eli Lilly and Company stock.
Show 3 earlier months
August 2026
11 events- Kazia Therapeutics Limited is seeking joint bookrunning management and co-management for a proposed offering, with Leerink partners and Needham & Company involved.
- Citigroup raised its rating on Innate Pharma stock, which trades on the Nasdaq exchange. Leerink Partners also upgraded the rating. MarketBeat aggregates the rating data.
- TD Cowen raised price targets for GoodRx stock.
- Financial analysts reviewed Biohaven's strategic asset sales and corporate strategy following its acquisition by Pfizer.
- Leerink partners provided research reports on AirSculpt Technologies on August 17, 2026.
- Leerink Partners cut price target on Stryker Corporation, and Norges Bank bought a new position in Stryker shares.
- Cantor Fitzgerald and Leerink Partners initiated analyst coverage on Avidity Biosciences on August 10, 2026.
- MarketBeat is providing consensus rating for Alamar Biosciences, and Leerink Partners and Bank of America have initiated coverage on the company.
- Halozyme's stock performance was mentioned in proximity to Leerink Partners on August 7, 2026.
- Leerink partners began its role as the lead book-running manager for an offering on behalf of BlossomHill Therapeutics, Inc. on August 1, 2026.
- Analyst downgrades are affecting Leerink partners' stock price, which is listed on the Nasdaq stock exchange.
July 2026
13 events- Scribe Therapeutics completed its IPO, led by Leerink Partners, with major backing from Eli Lilly and Andreessen Horowitz.
- Cantor Fitzgerald and Leerink partners issued rating changes for Replimune Group, Inc. on July 13, 2026.
- Analyst coverage is influencing stock price targets for companies including Bank of America, Eli Lilly and Company, Leerink partners, and Cantor Fitzgerald.
- LB Pharmaceuticals Inc is seeking institutional investment for a private placement, utilizing Leerink Partners as the placement agent, with BB Biotech as a key entity.
- Leerink partners adjusted its rating and target price for Medtronic plc on July 31, 2026.
- Scribe Therapeutics is based in Alameda, California, while Leerink Partners maintains an office in Boston, MA. The article also notes Goldman Sachs has an office in New York.
- Leerink Partners raised price target for Thermo Fisher Scientific Inc. (TMO) on July 23, 2026.
- SpaceX's IPO was expected to top US deals, with Jack Bannister identified as senior managing director at Leerink Partners.
- Leerink partners set a $152.00 target price on Encompass Health shares.
- Veradermics, Incorporated is facing market challenges in the US, with analyst reports affecting its stock price.
- Arcus Biosciences' stock rating and price were influenced by analyst reports, and the company filed with the SEC regarding institutional purchases.
- The Tennessee Department of Treasury bought a new position in stock, while Citigroup reaffirmed its 'outperform' rating and Leerink Partners set a $43.00 price objective.
- The FDA granted premarket approval for the LungFX device for use with United Therapeutics, while Leerink partners maintained an Outperform rating on the company's shares.
June 2026
6 events- Summit seeks FDA approval for its drug, which was presented at the ASCO meeting. The company is developing ivonescimab with Akeso.
- Intuitive Surgical received a Buy rating from Leerink partners, citing increased da Vinci placements and potential benefits from Trump-era tariffs.
- Analyst firm set price targets for Leerink partners' client, Twist Bioscience, on June 26, 2026. Concurrently, the CEO sold shares due to tax withholding obligations.
- A filing required by the SEC concerning McKesson Corporation shares, accompanied by analyst commentary.
- Analyst firm Leerink partners raised the price target for Roivant based on share count forecast on August 13, 2025.
- Leerink raised its price target for UnitedHealth Group stock.